8-KRegulation FDExhibits & Filings

Cencora, Inc. 8-K Report, Regulation FD Disclosure (May 1, 2017)

Filed May 1, 2017For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) announced on May 1, 2017, the execution of a significant new five-year contract with Express Scripts Holding Company. This agreement solidifies a key customer relationship for the company and ensures a substantial revenue stream over the next half-decade. The details of the agreement were disclosed via a press release, which is attached as an exhibit to the 8-K filing. Investors should note that this announcement primarily concerns a material customer contract renewal and expansion, rather than a financial performance update or significant corporate event. The company has explicitly stated that this information is furnished under Regulation FD and is not considered "filed" for purposes of Section 18 of the Securities Exchange Act, meaning it does not automatically trigger incorporation by reference into other SEC filings.

Key Highlights

  • 1Cencora, Inc. (formerly AmerisourceBergen) signed a new five-year pharmaceutical supply agreement with Express Scripts Holding Company.
  • 2The agreement is effective as of the announcement date and extends for a duration of five years.
  • 3This represents a critical renewal and extension of services for a major customer.
  • 4The announcement was made via a press release filed as Exhibit 99.1 to the 8-K.
  • 5The company has classified this disclosure under Regulation FD, not as a standard filing affecting its integrated disclosure under securities laws.
  • 6No specific financial terms or volumes were disclosed in this 8-K filing.
  • 7The filing does not contain any new financial statements or other exhibits beyond the press release.

Frequently Asked Questions

The primary purpose of this 8-K filing is to publicly announce and disclose the execution of a new five-year pharmaceutical supply agreement between Cencora, Inc. (formerly AmerisourceBergen Corporation) and Express Scripts Holding Company, in compliance with Regulation FD.

No, this 8-K filing and its accompanying press release do not provide specific financial terms, revenue projections, or volume commitments related to the new agreement with Express Scripts.

While the agreement secures a significant customer relationship for five years, this filing itself does not provide the necessary details to quantify the immediate or future impact on Cencora's reported financials. Investors would need to refer to future earnings reports and management commentary for such analysis.

These statements indicate that the information is being shared publicly to avoid selective disclosure. However, by stating it's 'not deemed filed,' the company is clarifying that this specific disclosure does not automatically update or become incorporated into prior SEC filings like registration statements or periodic reports, unless explicitly referenced later.